BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Investors in the cell therapy industry are actively looking in to solid tumours\, autoimmune indications and novel engineering as the be st place to allocate their money and resources. This\, along with the rec ent investments in Enara Bio\, ArsenalBio\, Kyverna and Artiva signifies that the field is poised to regain momentum.\n\nIt's not just investments that are gaining traction. Recent approvals are changing the game\, with Iovance and Adaptimmune making strides in treating solid tumours\, Kite securing first-line treatment approval\, and donor cell therapies\, demon strating success in putting autoimmune diseases into remission. The indus try is brimming with new hope!\n\nThe 8th CAR-TCR Summit Europe returns t o London this February as your must-attend forum to remain on the pulse o f recent innovation in cell therapy. Join us to collaborate\, innovate\, and overcome the shared challenges of safety concerns\, high cost of good s\, effective tumour targeting\, and more. Let's work together to drive s uccess in clinical trials\, secure regulatory approvals\, and position ce ll therapy as the first-line treatment for oncological and non-oncologica l indications.\n\nURLs:Website: \;https://go.evvnt.com/2712222-0?pid= 185Tickets: \;https://go.evvnt.com/2712222-2?pid=185Brochure: \;h ttps://go.evvnt.com/2712222-3?pid=185\n\nPrices:Conference + Autoimmune O R Regulatory Focus Day - Drug Developer : GBP 3597.00\,Conference Only - Drug Developer: GBP 2599.00\,Conference + Autoimmune OR Regulatory Focus Day - Start Up and Academic: GBP 2997.00\,Conference Only - Start Up and Academic: GBP 2199.00\,Conference + Autoimmune OR Regulatory Focus Day - Solution and Service Provider: GBP 5097.00\,Conference Only - Solution an d Service Provider: GBP 3899.00\n\nSpeakers: \;Aaron Edwards - Chief Executive Officer and Co-Founder - KiraGenBio\, Adrian Bot - Chief Scient ific Officer - Capstan Therapeutics\, Ali Mohamed - Senior Vice President - CMC Immatics\, Allen Feng - Founder and Chief Scientific Officer - Heb eCell Corp\, Andrew O'Leary - Senior Scientist Analytical Development - R esolution Therapeutics\, Birk Vanderween - Senior Vice President\, Global Manufacturing and Supply - Legend Biotech\, Blake Aftab - Chief Scientif ic Officer - Adicet Bio\, Chris Barkey - Chief Executive Officer - Swissf inity Group\, Christopher Murriel - Vice President\, Pre-Clinical Pharmac ology - ArsenalBio\, Cokey Nguyen - President and Chief Executive Officer - Atara Biotherapeutics\, Danielle Quarles - Executive Director\, Clinic al Operations - Sana Biotechnology\, David Fontana - Chief Operating Offi cer - Umoja Biopharma\, Deep Shah - Senior Director\, Regulatory Affairs - Sana Biotechnology\, Felix Lorenz - Chief Executive Officer / Chief Sci entific Officer - Captain T Cell\, Franco Locatelli - Professor\, Catholi c University of Sacred Heart - Bambion Gesu Children's Hospital\, Frederi k De Vos - Senior Director\, Quality Operations - Johnson and Johnson\, G eorge Coukos - Director\, Department of Oncology - University of Lausane\ , Greg Deener - Chief Executive Officer - iCell Gene Therapeutics\, Gwend olyn Binder - President\, Science and Technology - Cabaletta Bio\, Hemant Dhamne - Associate Director\, Process Development - Autolus\, Houman Deh ghani - Vice President\, Process and Analytical Development - Cabaletta B io\, Hugh Salter - Chief Scientific Officer - Anocca\, Jeff Liter - Found er and Chief Executive Officer - Luminary Therapeutics\, Jeffrey Jones - Chief Medical Officer - Cullinan Therapeutics\, Jenell Volkov - Senior Di rector\, Translational Medicine - Cabaletta Bio\, Jiri Eitler - Group Lea der - TU Dresden\, Kate Rochlin - Chief Operating Officer - IN8Bio\, Katj a Mohrs - Principal Scientist - Regeneron\, Kerstin Papenfuss - Head Phar ma Team - Deep Science Ventures\, Laurent Poirot - Senior Vice President\ , Immunology - Cellectis\, Leon Spijkers - Chief Executive Officer - Kore cyte Bio\, Leopold Sellner - Senior Director - Takeda\, Luise Weigand - H ead Of Research - Zelluna Immunotherapy\, Marc Davies - Vice President\, Research and Development - Leucid Bio\, Marc Guell - ICREA Research Profe ssor - University Pompeau Fabro\, Marlene Carrasco Alfonso - Global Head Immunology Cell Therapy - AstraZeneca\, Michael Bauer - Partner\, Novo Ho ldings - Venture Investments\, Nancy Boman - Chief Regulatory Officer - A dicet Bio\, Natalie Telizki - Chief Executive Officer - Swissfinity Group \, Omer Dushek - Founder - MatchBio\, Peggy Sotiropoulou - Chief Scientif ic Officer - T-knife Therapeutics\, Pierre Springuel - PhD Candidate - UC L\, Rachel East - Research Analyst - Beacon\, Raha Jahromi - Associate Di rector - Kite\, A Gilead Company\, Raphaël OGNAR President and CEO\, Co-f ounder - NKILT Therapeutics\, Rhine Shen - Senior Director\, Translationa l Medicine Kite\, A Gilead Company\, Senior Director\, Translational Medi cine - Kite\, A Gilead Company\, Rudolf Übelhart - Chief Scientific Offic er - Vanudis\, Shayoni Dutta - Data Science Manager - GSK\, Stefanos Theo haris - Chief Executive Officer - OneChain Immunotherapeutics\, Tiffany C hen - Vice President\, Discovery - GentiBio\, Vaishali Shukla - Head of C ell Therapy - Eli Lilly\n\nCategory: \;Conferences | Science\, Health and Medicine | Pharmaceuticals | Clinical\n\nDate and Time: \;25th F ebruary 2025 at 8:00 am to 27th February 2025 at 5:30 pm\n\nVenue details : \;ExCeL London\, 1 Western Gateway\, London\, England\, E16 1XL\, U nited Kingdom\n DTEND:20250227T173000 DTSTAMP:20260512T213552Z DTSTART:20250225T080000 LOCATION:ExCeL London\, 1\, Western Gateway\, London\, England\, E16 1XL\, SEQUENCE:0 SUMMARY:Investors in the cell therapy industry are actively looking into s olid tumours\, autoimmune indications and novel engineering as the best p lace to a... UID:90d6acad-7eab-4f7d-9ff5-31291c7eab47 END:VEVENT END:VCALENDAR